To confirm that the restricted tumor progression of Slc7a11-KD tumor cells mainly relies on improved CD8+ T-cell functionality and fitness, we thus depleted CD8+ T cells in vivo with αCD8 antibody (Supplementary Fig. 3i, j). The gene discussed is CD8A; the disease is neoplasm.